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MDA-MB-435S human breast cancer cells (435S) secrete nucleoside diphosphate kinase (NDPK) that supports metastases and is
inhibited by epigallocatechin gallate (EGCG) and ellagic acid (EA). We hypothesise that 435S cell-secreted NDPK-B supports tumour
formation by modulating ATP levels locally to activate endothelial cell (EC) P2Y receptor-mediated angiogenesis. Epigallocatechin
gallate (IC50¼8–10mM) and EA (IC50¼2–3mM) suppressed 435S cell growth, but had less effect on human CD31
þ EC growth.
Epigallocatechin gallate (IC50¼11mM) and EA (IC50¼1mM) also prevented CD31
þ EC tubulogenesis on Matrigelt. 435S cell-
conditioned media induced tubulogenesis in a cell number, time, and nucleotide-dependent manner. Ellagic acid (1mM), but not
equimolar EGCG, reduced cell number-dependent angiogenesis. P2Y1 receptor activation by NDPK-generated nucleotide (100mM
ATP) or by 10mM 2-methyl-thio-ATP (2MS-ATP) promoted tubulogenesis on collagen and was blocked by the P2Y1 antagonist
MRS2179 (10mM). Physiological amounts of purified as well as 435S cell-secreted NDPK also promoted angiogenesis that was
attenuated by NDPK depletion or 10mM MRS2179, indicating a P2Y1 receptor-mediated pathway. These results support the notion
that secreted NDPK mediates angiogenesis via P2Y receptor signalling and suggests that novel inhibitors of NDPK may be useful as
therapeutics.
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The onset of tumour vascularisation, the ‘angiogenic switch’,
supplies the tumour with nutrients and oxygen that promote
growth. It is known that tumours in a pre-vascularised state
are unable to grow beyond 2–3mm
3 (approximately 10
5–10
6 cells)
in size where a balance between active proliferation and apoptosis
keeps the tumour in an arrested state of growth (Holmgren
et al, 1995). Conventional treatment modalities targeting the
genetically instable cancer cells are burdened with toxicity and
the emergence of drug-resistant cell types. Directly targeting
the genetically stable vascular endothelial cells (ECs) involved
in tumour-mediated angiogenesis has shown promise when
co-administered with conventional cancer therapies (Clinical
Trials, 2006). It has been suggested that angiogenic therapies
initially normalise the vasculature and thus sensitise tumours to
concurrently administered chemo/radiotherapies resulting in
synergistic outcomes (Jain, 2001; Tong et al, 2004). Since women
who succumb to breast cancer have often undergone surgery to
remove the primary tumour, antiangiogenic therapies may be
considered essential in combating the metastatic spread often seen
years later.
Nucleoside diphosphate kinase (NDPK) (EC 2.7.4.6), the protein
product of gene nm23, was first described as an intracellular
‘housekeeping’ enzyme, which covalently transfers the g-phosphate
from a nucleoside triphosphate to a nucleoside diphosphate. While
expression of nm23-H1 (NDPK-A) and nm23-H2 (NDPK-B) have
been examined, less attention to their enzymatic function in cancer
and metastasis has been considered. Nucleoside diphosphate
kinase is known to be distributed in the cytosol and plasma
membrane of cells, as well as the nucleus (Bertheau et al,
1994) where the NDPK-B isoform functions as PuF, a c-MYC
transcription factor (Postel, 2003). Non metastatic clone 23 gene,
nm23, was first observed in murine carcinoma cell lines and said to
negatively correlate with a cancer’s metastatic potential (Roymans
et al, 2002), although there is evidence to the contrary (Postel,
2003). We have shown that both MDA-MB-435S and -231
metastatic human breast carcinoma cells secrete NDPK-B
into their surrounding environment when cultured in vitro
(Anzinger et al, 2001). Nucleoside diphosphate kinase is secreted,
despite the lack of a signal sequence, probably via non-classical
export as has previously been reported with proangiogenic
fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) (Nickel,
2003). The transphosphorylation activity of NDPK-B has been
reported to promote the metastatic potential of human melanoma
cells (Hamby et al, 2000).
The anticarcinogenic potential of catechins (polyphenols found
in green tea) was first observed and reported over a decade ago.
Epigallocatechin gallate (EGCG) has been identified as the major
catechin in green tea and shown to inhibit both the growth of
various cancers (Liang et al, 1999; Suganuma et al, 1999), and
angiogenesis (Cao and Cao, 1999; Singh et al, 2002). We have
previously shown that EGCG and ellagic acid (EA) are more potent
inhibitors of NDPK activity than known nucleoside analogues
(Malmquist et al, 2001) and have suggested a role for NDPK
inhibition in the management of metastasis (Anzinger et al, 2001).
A role for NDPK activity in blood vessel regulation is known. The
Nucleotide Axis Hypothesis posits that ecto-NDPK on vascular ECs
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sfacilitates the regulation of extracellular nucleotide levels (e.g.,
ATP) (Buxton et al, 2001; Kaiser and Buxton, 2002). Since
perturbing the regulation of nucleotide levels has been shown to
impair angiogenesis (Goepfert et al, 2001; Moser et al, 2001), we
hypothesise that extracellular NDPK takes an advantage of
nucleotide signalling on vascular ECs and promotes pathological
angiogenesis.
Heterotrimeric G-protein-coupled ATP receptors (P2Y) are
recognised as integral modulators of platelet aggregation and
blood flow regulation. Extracellular ATP activates P2Y receptors
on vascular ECs to release vasoactive mediators such as nitric
oxide, prostacyclin, and additional ATP (Yang et al, 1994; Buxton
et al, 2001) which can also elicit angiogenic effects (Kashiwagi et al,
2005). Here, we provide evidence that human breast cancer cell-
secreted NDPK promotes EC tubulogenesis in vitro. This supports
our hypothesis that NDPK-mediated increases in extracellular
ATP levels by breast tumour cells provide a mechanistic basis by
which targeted therapeutics can prevent tumour growth and
angiogenesis.
MATERIALS AND METHODS
Cell culture
The human breast cancer cell line MDA-MB-435S (435S) was
purchased from the American Type Culture Collection (Manassas,
VA, USA). Human cardiac ECs were previously isolated by
fluorescence-activated cell sorting (FACS) for CD31 (PECAM)
and immortalised by human telomerase reverse transcriptase
(hTRT) – referred to as CD31
þ cells. Unless specifically stated,
both cell types were maintained and incubated in Dulbecco’s
modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA)
supplemented with 10% fetal bovine serum (FBS) (Atlanta
Biological, Lawrenceville, GA, USA), penicillin–streptomycin,
(1500Ul
 1–100mgl
 1) and 0.5mgl
 1 Fungizone (Invitrogen,
Carlsbad, CA, USA) at 371C in a humidified 5% CO2/95% air
atmosphere.
Effect of EGCG and EA on MDA-MB-435S and CD31
þ cell
growth
To determine if EGCG and/or EA (Sigma, St Louis, MO, USA)
inhibit 435S cell growth, 1.2 10
5 cells per well were seeded onto
six-well tissue culture plates and incubated in the presence of
EGCG or EA (0.3–30mM) for 2–5 days. For longer incubation
periods (i.e., days 4 and 5) culture media were replaced after 72h
with fresh media containing appropriate ECGC or EA concentra-
tions. To determine if EGCG and/or EA inhibit CD31
þ cell growth,
9.6 10
4 cells per well were first seeded onto six-well tissue culture
plates and incubated for 24h. Culture media were then replaced
with fresh media containing EGCG or EA (0.3–10mM) and
incubated for 24h. At desired treatment end points, EGCG and
EA (2–5 days and 24h, respectively) treated cells were counted
using a Coulter Z1 cell counter (Coulter Corp, Hialeah, FL, USA)
and compared to non-treatment controls.
In vitro angiogenesis scoring technique
CD31
þ cell tubulogenesis (i.e., tubule-like formation in culture)
was quantified using a high-resolution digital camera (FujiPro 2;
12 mega pixel) attached to a Nikon 300 inverted microscope to
document CD31
þ cell tubule-like formations. An angiogenesis
score was obtained by analysing digital images ( 100) collected
from the central pointing corners of quadrants I–IV in each well
and averaging the four scores. Each angiogenesis score represents
the product of mean number of branch points multiplied by mean
branch length multiplied by mean cell surface area (illustrated in
Figure 1). Morphometry (in pixels) was performed using
MetaMorph image analysis software (V4.01; Universal Imaging
Corporation, Downingtown, PA, USA). The lengths of tubule-like
formations were measured for all completely visible connections
between edges of aggregate bodies (Figure 1A). The number of
branch points connecting one aggregate body to other aggregate
bodies (usually 1–3) was counted when the complete connection
was within view of the image (Figure 1A). The total CD31
þ cell
surface area was also determined from these images (Figure 1B).
Number of branch points (bp), length (l), and cell surface area (a)
were multiplied to produce a relative angiogenesis score (s). Thus,
s¼bp l a.
Effect of EGCG and EA on angiogenesis
Four-well glass slide chambers were coated with a thin layer
(B10ml) of Matrigelt (BD Biosciences, Bedford, MA, USA) and
allowed to solidify at 371C/5% CO2 for 30min. To determine if
EGCG and/or EA inhibit CD31
þ cell tubulogenesis, 5 10
4 cells
were first seeded onto four-well glass slide chambers coated with
Matrigel and allowed to attach for 30min at 371C/5% CO2. The test
substances EGCG or EA (0.3–30mM) were then added to the
individual wells as appropriate and incubated with CD31
þ cells
for 5.5h. The antiangiogenic drug endostatin (Sigma), 0.1–
1.0mgml
 1, was used as a positive control. Non-treatment controls
Branch points from
aggregate body 
Tubule lengths and
total coverage area 
B
A
Figure 1 Angiogenesis scoring. (A) Tubule lengths (l) and number of
branch points (bp). (B) Endothelial cell (EC) surface area (a). Relative
angiogenesis score (s)¼bp l a. Photographs were imaged at a
magnification of  100.
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EA effects on in vitro angiogenesis.
Effect of MDA-MB-435S cell-conditioned media on
angiogenesis
To determine if secreted molecules from 435S cells promote
CD31
þ in vitro angiogenesis, 435S cells were seeded onto
Transwellt tissue culture inserts (3.0mm pores; Corning, Acton,
MA, USA) for incubation times up to 24h. These various
conditioned media were examined via the above described
CD31
þ cell Matrigel tubulogenesis assay using 24-well tissue
culture plates. Briefly, 435S cell number (1.5–6 10
4 cells
incubated for 12h) and conditioning time (6 10
4 cells incubated
for 30min to 24h) were used as experimental variables. At their
incubation end points, the various conditioned media were frozen
at  301C and later assessed for their effects on in vitro
angiogenesis.
Effect of EGCG and EA on MDA-MB-435S cell-conditioned
media promoted angiogenesis
The conditioned media from 1.5 10
4 to 6 10
4 435S cells
incubated for 12h was further investigated with the addition of
either 1mM EGCG or EA. These experiments were conducted using
the CD31
þ cell Matrigel tubulogenesis assay on 24-well tissue
culture plates. Endostatin (1.0mgml
 1) was used as a positive
antiangiogenic control. Non-treatment controls were performed
for normalisation and comparison.
Effect of apyrase on MDA-MB-435S cell-conditioned media
promoted angiogenesis
The conditioned media from 6 10
4 435S cells incubated for
60min was also further investigated with the addition of potato
apyrase (grade 1; Sigma; EC 3.6. 1.5). Briefly, the 435S cell-
conditioned media were incubated in a final concentration of
0.75U apyrase per millilitre conditioned media for 5min at 371C
(1U liberates 1.0mmol orthophosphate from ATP or ADP per min
at pH 6.5, 301C). This conditioned media pretreated with apyrase
was then observed in the CD31
þ cell Matrigel tubulogenesis assay
onto 24-well tissue culture plates. Non-treatment controls were
performed for normalisation and comparison.
Effect of ATP and 2-methyl-thio-ATP on angiogenesis
The following experiments were performed with a lower concen-
tration of FBS supplementation (2 vs 10%) and collagen instead of
Matrigel to rule out the role of angiogenic factors present in
Matrigel to more clearly distinguish the amount of proangiogenic
stimulation attributed to P2Y receptor activation alone. To
determine if 2-methyl-thio-ATP (2MS-ATP) and/or ATP (Sigma)
stimulate in vitro angiogenesis, 3 10
4 CD31
þ cells per well were
first seeded onto 24-well tissue culture plates coated with
1mgml
 1 collagen (Rat type I; BD Biosciences) and allowed to
attach for 30min. The P2Y receptor agonists 2MS-ATP (P2Y1R;
10mM) and ATP (P2Y1/2R; 100mM) were added to their respective
wells and incubated with CD31
þ cells for 24h. CD31
þ cell
tubulogenesis was also observed in the presence of 10mM MRS2179
(P2Y1R antagonist; Sigma) with either 10mM 2MS-ATP or 100mM
ATP. Endothelial growth medium-2 (EGM-2t; Clonetics, East
Rutherford, NJ, USA) was used as a positive control to confirm
that this modified assay could successfully detect angiogenic
stimulation. Non-treatment controls were performed for normal-
isation and comparison. This experiment was repeated with
2 10
4 CD31
þ cells per well and incubated for a longer duration
of 72h.
Preparation of human breast carcinoma secreted NDPK
extract
MDA-MB-435S cells were grown to B75% confluence in T150
tissue culture flasks and then washed  3 with room air Krebs
buffer (RAK) containing (in mM) 120 NaCl, 5 KCl, 0.587, KH2PO4,
0.589 Na2HPO4, 2.5 MgCl2,2 0a-D-glucose, 2.5 CaCl2, 25 Tris, and 5
NaHCO3. The cells were then slowly rocked and incubated in RAK
at 371C for 90min. This RAK containing secreted NDPK-B was
concentrated for 30min at 41C and 2000g using Amicon Ultra-15
10kDa Centrifugal Filters (Millipore Corporation, Bedford, MA,
USA). The remaining liquid captured above the 10-kDa mark was
once again filtered as described above. The concentrated (B200-
fold) 435S cell-secreted NDPK extract was frozen at ( 801C) and
used in subsequent angiogenesis experiments. The average protein
concentration for 1  NDPK extract (19.23mgml
 1) was used to
mimic the approximate amount of secreted NDPK-B seen in the
conditioned media of B75% confluent 435S carcinoma cell
cultures. Nucleoside diphosphate kinase transphosphorylation
activity; ATP production from GTP donor and ADP acceptor
was measured using a luciferin–luciferase ATP detection assay
(Sigma). Using only ADP and no GTP donor in our activity
assay showed no ATP production, indicating that adenylate
kinase activity was not responsible for the ATP production
observed (not shown).
Effect of purified NDPK on angiogenesis
To determine if purified NDPK promotes in vitro angiogenesis,
3 10
4 CD31
þ cells per well were first seeded onto 24-well tissue
culture plates coated with 1mgml
 1 collagen (Rat type I) and
allowed to attach for 30min. Semi-purified bovine liver NDPK
(Sigma) and subsequent affinity purified NDPK transphosphoryla-
tion activity levels; as measured using a luciferin–luciferase ATP
detection assay were used to match the activity level of 1  435S
cell-secreted NDPK extract. This purified NDPK with or without
nucleotide donor and acceptor (300mM GTP and 30mM ADP,
respectively) were then added to wells and incubated with the
CD31
þ cells for 24h. EGM-2 was used as a positive control, while
non-treatment controls were performed for normalisation and
comparison.
Effect of MRS2179 on NDPK extract induced angiogenesis
To determine if MRS2179 (P2Y1R antagonist) reduces the degree
which 435S cell-secreted NDPK extract promotes in vitro
angiogenesis, 3 10
4 CD31
þ cells per well were first seeded onto
24-well tissue culture plates coated with 1mgml
 1 collagen (Rat
type I) and allowed to attach for 30min. 1  NDPK extract with or
without 10mM MRS2179 was then incubated with the CD31
þ cells
for 24h. EGM-2 was used as a positive control, while non-
treatment controls were performed for normalisation and compar-
ison. This experiment was also repeated with 2 10
4 CD31
þ cells
per well in experiments lasting 72h.
Statistical analyses
All graphs were prepared using Prism Graphing Software (V4.03;
GraphPad Software, San Diego, CA, USA) and statistical analyses
were performed using InStat Statistical Software (V3.0; GraphPad
Software), with Po0.05 considered to be statistically significant.
All growth and angiogenesis scores were tested for statistical
significance using ANOVA and Kruskal–Wallis multiple compar-
isons post-test unless otherwise stated. Data points and error bars
represent means±s.e.m. *Po0.05; **Po0.01; ***Po0.001 (vs
negative control);
þPo0.05 (EGCG vs EA);
#Po0.05;
##Po0.01
(vs 435S cell stimulation).
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Epigallocatechin gallate and EA suppress MDA-MB-435S
cell growth
435S cells incubated with 3mM EGCG over 5 days inhibited growth
B10–20%, while equimolar EA was more effective with B50–60%
growth suppression. Ellagic acid but not EGCG significantly
inhibited cell growth at 3mM when compared to non-treatment
controls (Pp0.001; Figure 2A). The addition of 10mM EGCG for 5
days inhibited growth B45–65%, while equimolar EA was more
effective producing B80–90% suppression. Both EA and EGCG
treatments significantly impeded cell growth at 10mM when
compared to non-treatment controls (Pp0.05; Figure 2B). 435S
cells incubated with 0.3–30mM EGCG or EA over 2 days produced
dose-dependent inhibition of growth with an apparent IC50 for
EGCG of B8mM and an IC50 for EA of B2mM (day 5 EGCG IC50 of
B10mM and EA IC50 of B3mM; data not shown). Treatment with
EAX1mM over 2 days significantly suppressed cell growth when
compared to non-treatment control (Pp0.05; Figure 2C) and at a
B1/2 log higher potency than EGCG (3mM vs 10mM¼approxi-
mately 60% inhibition). At micromolar concentrations, both
agents were cytostatic rather than cytotoxic since cells regrew
when drug was removed.
Epigallocatechin gallate and EA suppress human EC
growth and tubule-like formations on Matrigel
CD31
þ cells incubated with 0.3–10mM EGCG or EA for 24h
produced dose-dependent inhibition of growth. The addition of
EGCG or EA significantly suppressed growth B35–45% at
concentrations X3mM when compared to non-treatment control
(Pp0.05; Figure 3A). CD31
þ cells incubated on Matrigel with 0.3–
30mM EGCG or EA produced dose dependent inhibition of in vitro
angiogenesis with an apparent IC50 for EGCG of B11mM and a
more potent IC50 for EA of B1mM. Addition of EA significantly
reduced angiogenesis when compared to non-treatment control
(Pp0.01; Figure 3B and C). Unlike growth inhibition, EA
suppressed CD31
þ cell tubulogenesis at approximately one log
lower concentration than EGCG (3mM vs 30mM¼B70% inhibi-
tion). Endostatin, the antiangiogenic control, produced dose
dependent and significant inhibition of angiogenesis at 1mgml
 1
comparable to concentrations X3mM of EGCG and EA (Pp0.05;
data not shown).
MDA-MB-435S conditioned media promotes in vitro
angiogenesis in a time-, cell number-, and
nucleotide-dependent manner
We examined the effect of 435S cell-conditioned media on CD31
þ
cell tubulogenesis and its inhibition by polyphenolic compounds.
Media containing secreted NDPK-B (conditioned media) were
collected using a Transwellt apparatus seeded with 435S cells.
CD31
þ cells incubated with 12-h conditioned media (varying 435S
cell number from 1.5 10
4 to 6 10
4) on Matrigel demonstrated a
progressive induction of angiogenesis with increasing numbers of
435S cells. A ratio of X75 MDA-MB-435S cells per microlitre
(4.5 10
4 cells) significantly promoted angiogenesis at least two-
fold when compared to control media conditioned without breast
cancer cells (Pp0.05; Figure 4A). CD31
þ cells incubated with
media conditioned by 6 10
4 435S cells (varying conditioning
times – 30min to 24h) on Matrigel indicated an initial B5-fold
induction burst of in vitro angiogenesis, which eventually returned
to control-like levels after 24h. Generally, conditioning times up to
12h significantly promoted CD31
þ cell tubulogenesis (Pp0.05;
Figure 4B).
The promotion of tubulogenesis by 12h 435S cell-conditioned
media (varying cell number) was diminished B45–60% by 1mM EA,
B20–30% by 1mM EGCG, and B5–35% by 1mgml
 1 endostatin.
Only the addition of EA to 435S-conditioned medium significantly
reduced this cell number-dependent angiogenesis relative to
controls (Pp0.05; Figure 4C). Using a luciferin–luciferase ATP
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Figure 2 Epigallocatechin gallate (EGCG) and ellagic acid (EA) inhibit human breast cancer growth in vitro.( A and B) EA treatment reduced cell number
when compared to equimolar amounts of EGCG. (C) EA treatment over 2 days reduced cell number at one half-log higher potency than EGCG. Control;
435S cells incubated in CDMEM supplemented with 10% FBS. Control mean¼212806±35642 435S cells.
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sdetection assay we also determined that 0.1–1.0mgml
 1 endostatin,
our antiangiogenic control, did not inhibit the activity of 435S-
secreted NDPK-B (data not shown) in contrast to EGCG and EA.
Overall, 1mM EA produced better inhibition of in vitro angiogenesis
induced by MDA-MB-435S cells than equimolar EGCG.
The observed promotion of tubulogenesis by 60-min condi-
tioned media (6 10
4 435S cells; Pp0.05; Figure 4D) was
attenuated back to control levels with the addition of 0.75U
apyrase per ml media. This degradation of nucleotides (i.e., ATP
and ADP) by the apyrase enzyme blocked the B2.9-fold induction
above controls. The addition of apyrase to non-conditioned
control media had no effect (data not shown).
Purified and MDA-MB-435S secreted NDPK induce
angiogenesis
Incubation of CD31
þ cells for 24h with semi-pure and purified
bovine liver NDPK (activity matched to 1  435S cell-secreted
NDPK extract) increased in vitro angiogenesis at least B1.7- and
B1.3-fold above control levels, respectively (Figure 5A and B).
Angiogenic stimulation control EGM-2 further stimulated tubulo-
genesis two-fold above control. The semi-pure bovine liver NDPK
was purified B12.5-fold, based on specific transphosphorylation
activities, using an EDA-ATP sepharose column (Jena Bioscience,
Germany). The combination of bovine liver NDPK, GTP (donor),
and ADP (acceptor) induced tubulogenesis greater than that of
NDPK alone. GTP and ADP alone induced a modest increase in
tubulogenesis consistent with P2Y receptor activation (data not
shown).
Progressive immunodepletion of NDPK-B from the 435S cell-
secreted NDPK extract suppressed CD31
þ cell tubulogenesis on
collagen up to 65% when compared to non-depleted extract
(Figure 5C), the depleted transphosphorylation activities were
measured and compared to starting material using the luciferin–
luciferase ATP detection assay. The significant increase in
angiogenesis induced by 435S cell-secreted NDPK extract at 24h
was similar to the B2.0-fold stimulation seen with 10mM 2MS-ATP
or 100mM ATP (Pp0.01; Figure 5D) and blocked by 10mM
MRS2179 (B1.2-fold control). The 72-h assay produced a B2.3-
fold increase in tubulogenesis after the addition of NDPK extract
(Pp0.05; Figure 5E) and a reduction back to B1.3-fold in the
presence of 10mM MRS2179.
P2Y receptor activation on human ECs stimulates
angiogenesis
CD31
þ cells incubated for 24h with 10mM 2MS-ATP (P2Y1R
agonist) or 100mM ATP (P2Y1/2R agonist) indicate a similar,
significant B2.0-fold induction of in vitro angiogenesis above
control levels comparable to the angiogenic stimulation control
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Figure 3 Epigallocatechin gallate (EGCG) and ellagic acid (EA) inhibit human EC growth and angiogenesis in vitro.( A) Both EGCG and EA reduced
CD31
þ cell number when incubated for 24h at X1mM. Control A mean¼163094±27859 CD31
þ cells. (B) EA was more potent than EGCG in
reducing CD31
þ cell tubulogenesis over 6h. Control B mean¼12078.1±3355.3 angiogenesis units. (C) Representative images illustrating endostatin,
EGCG, and EA inhibition of tubule-like formations ( 100 magnification). Control; CD31
þ cells incubated in CDMEM supplemented with 10% FBS.
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sEGM-2 (containing VEGF) (Pp0.001; Figure 5D). CD31
þ cells
incubated for 72h with 100mM ATP demonstrate a significant
B2.5-fold induction of tubulogenesis above control levels, while
the EGM-2 control produced a B3.6-fold increase over control
(Pp0.05; Figure 5E). The use of 100mM 2MS-ATP and 1mM
ATP produced no increase in stimulation over 10mM 2MS-ATP
or 100mM ATP alone (data not shown). The addition of
10mM MRS2179 (P2Y1R antagonist) to either 10mM 2MS-ATP or
100mM ATP stimulations diminished tubulogenesis back to
near control levels (Figure 5D) after 24h, while the addition
of this P2Y1R antagonist over a 72h period only suppressed
ATP angiogenic stimulation back down to B1.5-fold that of
control (Figure 5E). MRS2179 (10mM) showed no effect on
tubulogenesis by itself (data not shown). We chose 10mM
MRS2179 as maximal inhibition of P2Y1 receptor activation on
ECs, consistent with our findings and those of others (Boyer et al,
1998; Baurand et al, 2001; Kaiser and Buxton, 2001, 2002) in EC
systems. Varying concentrations of MRS2179 (0.1–10mM) did
not affect NDPK transphosphorylation activity (data not shown),
indicating P2Y1R antagonism as the primary mode of angiogenic
inhibition.
DISCUSSION
Our results demonstrate that both EA and EGCG inhibit MDA-MB-
435S human breast cancer cell growth in a dose-dependent
manner, consistent with the results of others (Suganuma et al,
1999; Seeram et al, 2005). Both EGCG and EA are near equipotent
in suppressing CD31
þ EC in vitro angiogenesis and 435S cell
growth, while less potent in inhibiting CD31
þ EC growth. The
disparate effect of polyphenols between EC growth inhibition and
tubulogenesis suppression suggests that P2Y signalling may be
critical in the complex process of tubulogenesis, while EC growth
could be less dependent on P2Y mediated effects of these
compounds. Therefore, we utilised the CD31
þ cell tubulogenesis
assay as a measure reflecting in vivo angiogenesis.
We observed that 435S cells promote in vitro angiogenesis in a
cell number dependent manner. Furthermore, EA4EGCG attenu-
ated this proangiogenic effect. The initial antiangiogenic properties
attributed to EA and EGCG (when incubated with non-conditioned
media) are distinct from their increasing capacity to suppress the
CD31
þ cell tubulogenesis promoted by increasing numbers of
435S cells, thus suggesting another mode of action. Given that
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Figure 4 Human breast cancer cell-conditioned media promotes in vitro angiogenesis. CD31
þ EC were incubated on Matrigelt with media conditioned
by MDA-MB-435S cells (varying conditioning time or cell number) and tubulogenesis was observed after 6h. (A) increasing 435S cell number induced in vitro
angiogenesis. Control A consisted of CDMEM supplemented with 10% FBS and conditioned for 12h with no 435S cells. Control mean¼2581.5±374.6
angiogenesis units. (B) shorter 435S cell conditioning time stimulated in vitro angiogenesis. Control B consisted of CDMEM conditioned for 24h with no
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diminished 435S cell number dependent in vitro angiogenesis. Control C consisted of CDMEM conditioned for 24h with no 435S cells. Control
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sEGCG has been shown to inhibit cancer-associated enzymes
such as matrix metalloproteinases (MMPs) (Yamakawa et al, 2004)
and the proteasome (Kazi et al, 2004), we suggest that EGCG
and EA inhibition of secreted NDPK-B is another anticancer
and antiangiogenic property that can be attributed to these
polyphenolic compounds. We propose that EA’s potency as an
NDPK-B inhibitor and the subsequent reduction of extracellular
ATP levels (Yang et al,1 9 9 4 ;M a l m q u i s tet al, 2001) may, in part
explain why EA is a more potent inhibitor of CD31
þ cell
tubulogenesis than is EGCG. Known antiangiogenic levels of
endostatin did not inhibit NDPK transphosphorylation activity
and its diminishing effectiveness in suppressing in vitro angiogenesis
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Figure 5 Extracellular nucleoside diphosphate kinase (NDPK) and EC P2Y1 receptor activation induce angiogenesis in vitro.( A and B) semi-pure as well
as purified bovine liver NDPK induced CD31
þ cell tubulogenesis over 24h. Statistical significance versus control was determined using the Mann-Whitney
test. (C) NDPK-B derived from 435S cell-secreted NDPK extract promoted in vitro angiogenesis over 72h at various depletion levels. Control C
mean¼2645.9 angiogenesis units. (D) 24h incubation with ATP, 2MS-ATP, and NDPK extract all stimulated angiogenesis; blocked by MRS2179. Control D
mean¼6183.8±1840.4 angiogenesis units. (E) 72h incubation with ATP and NDPK extract both promoted angiogenesis; blocked by P2Y1R antagonist,
MRS2179. Control E mean¼1256.6±240.9 angiogenesis units. Controls consisted of CD31
þ cells incubated in CDMEM supplemented with 2% FBS. The
angiogenic stimulation control used was endothelial growth media-2 (EGM-2t) containing VEGF.
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sin response to increasing numbers of 435S cells, further suggests
that breast cancer cell-secreted NDPK may play an important role
in promoting angiogenesis. One other possible explanation
consistent with our hypothesis would be that these compounds
also block the activation of nucleotide receptors. However,
radioligand binding competition studies with EC P2Y1R do not
support this possibility (data not shown). Epigallocatechin gallate
and EA are potent but non-specific inhibitors of NDPK transpho-
sphorylation activity; therefore, we explored further the extra-
cellular nucleotide aspect of our secreted NDPK angiogenesis
model. Supporting this hypothesis, we found that the degradation
of ATP and ADP by apyrase suppressed the ability of 435S cell-
conditioned media to induce in vitro angiogenesis.
We observed decreased tubulogenesis levels with increasing
conditioning durations with 435S cells. This negative correlation is
not clear mechanistically, but does not argue against the presence of
a paracrine and/or autocrine proangiogenic effect in vivo since if in
the blood stream, such effects would be expected to take place
adjacent to endothelium diluted by blood flow and thus would not
accumulate but would be replenished by NDPK-B protein secretion.
Nucleoside diphosphate kinase’s extracellular role may be
underappreciated in carcinogenesis especially in tumour angiogen-
esis, as indicated by the plethora of studies involving only its
intracellular actions. The secretion of NDPK orthologues by
intracellular parasites as a possible survival tactic (Gounaris et al,
2001; Chopra et al, 2003) and the secretion of NDPK by various
solid and haematological malignancies (Anzinger et al, 2001; Okabe-
Kado and Kasukabe, 2003) lead us to propose the pathological role
of secreted NDPK in promoting cancer and tumour angiogenesis.
Extracellular NDPK in the tumour vasculature would elevate
nucleotide signalling and subsequent release of vasoactive factors
with angiogenic effects (Ziche and Morbidelli, 2000). In support of
our hypothesis, a positive correlation between the regulation of P2Y
signalling and various angiogenic properties (Moser et al,2 0 0 1 ;
Tanaka et al, 2004; Kaczmarek et al, 2005) is known.
Our results with purified NDPK, (a mixture of NDPK-A and -B),
together with the observation that both NDPK isoforms are
secreted by various cancers suggests that the transphosphorylation
activity of NDPK and not its isoform is crucial. We tested human
breast cancer secreted NDPK and observed that NDPK-B depletion
from 435S cell-secreted NDPK extract progressively reduced its
ability to promote CD31
þ cell tubulogenesis. The release of NDPK
into the incubation buffer is not the result of cell death, since we
determined that greater than 10% of cells would need to undergo
complete lysis (not apoptosis) during our 90min collection to
obtain similar levels of transphosphorylation activity to NDPK
extracts (data not shown). Moreover, when examined after extract
collection, cultures are healthy and can be returned to the
incubator and observed to be viable. ATP synthase does not
account for ATP production as we used an extract devoid of intact
cells or membranes. Conditioned media did not contain adenylate
kinase activity. Autophosphorylation assays (Backer et al, 1993)
have been used to monitor NDPK transphosphorylation activity;
we employed a phosphoryl transfer assay because it produces
kinetic data and can determine relative inhibition. The trans-
phosphorylation activity assay has shown that 435S NDPK-B
extract and purified bovine liver NDPK have approximately the
same Km (B30mM) for ADP (Anzinger et al, 2001).
We observed that 435S cell-secreted NDPK extract and P2Y1R
activation induce significant in vitro angiogenesis and do so to a
similar degree. The use of 10mM 2MS-ATP or 100mM ATP in
promoting CD31
þ cell tubule-like formations was maximal, likely
due to known desensitisation of P2Y1/2 receptors at higher agonist
concentrations (Ralevic and Burnstock, 1998). MRS2179 blockade
of CD31
þ cell P2Y1R activation stimulated with 435S cell-secreted
NDPK extract provides strong evidence that human breast cancer-
secreted NDPK reaction product provides a proangiogenic signal
via P2YR activation (e.g., ATP). The addition of MRS2179 still
allowed minimal angiogenic stimulation over negative control,
suggesting that P2Y signalling works in concert with other
angiogenic pathway(s) that are yet to be elucidated.
The role of nm23-H2 in promoting metastasis is supported by the
observation that a catalytically inactive mutant of NDPK-B
significantly suppressed the lung metastasis of human melanoma
cells in vivo (Hamby et al, 2000). Recent work indicates that
activated P2Y2R’s associate and transactivate vascular endothelial
growth factor receptor-2 (VEGFR2) (Seye et al, 2004), directly linking
nucleotide receptor activation to established tumour angiogenesis
signalling (VEGF-VEGFR signalling). P2Y receptor potentiation of
VEGFR2 signalling therefore may be essential in describing the
angiogenic properties of nucleotides such as ATP. P2Y and VEGF
receptors being colocalised to caveolar domains in the cell
membrane allows the potential of a substantial proangiogenic signal
with small amounts of agonist stimulation (Kaiser et al, 2002).
P2YR signalling is a tumour angiogenesis and metastasis
mechanism which 435S cells exploit. Since cells secrete pre-
phosphorylated NDPK-B (Anzinger et al, 2001), ATP generation
locally in vivo may require little substrate and donor (a triphospho-
nucleotide such as GTP) may be intracellular. Our model predicts
two spatially distinct yet conceptually dependent mechanisms:
NDPK recycling of ADP back to ATP in both arteries and
capillaries. Nucleoside diphosphate kinase in the arteries may
elevate local nucleotide ATP concentrations to produce P2YR-
mediated vasodilation and anti-platelet aggregation, advantageous
to the transit of cancer cells to secondary sites. Nucleoside
diphosphate kinase secretion in capillaries may elevate local
nucleotide concentrations and produce nucleotide receptor (e.g.,
P2Y) mediated angiogenesis (Figure 6). As an example supporting
this hypothesis we provide evidence that extracellular NDPK
induces EC tubulogenesis predominately via P2Y1R. Elevated levels
of ATP and subsequent P2YR activation will release additional
ATP to prolong the angiogenic effect (Yang et al, 1994). The
constant elaboration of NDPK-B by 435S cells facilitates the
chronic and increased activation of P2Y signalling, producing
pathological angiogenesis in tumour vasculature. Since the
NDPK-B enzyme can be expressed as both an ecto- or exo-enzyme
and help to regenerate 8–12% of ADP in blood back to ATP
(Buxton et al, 2001), it may play a significant role in angiogenic
regulation especially in the setting of apoptosis and necrosis
Cancer cell NDPK ATP Tumour angiogenesis  Metastasis?
Endothelium
ATP
Cancer cell
AMP
NDPK
ADP
P2YR
ADO
P1 P2YR
ATP ADP AMP ADO
NO NO
NO NO NO
ADP
ATP
P1
ADP NDPK NDPK
Inhibition of
kinase activity
Figure 6 Putative role of extracellular nucleoside diphosphate kinase
(NDPK) and P2Y receptor activation in tumour angiogenesis. We
hypothesise that breast cancer secreted NDPK-B is an important
contributor to promoting angiogenesis and metastasis. Extracellular NDPK
would modulate nucleotides such as elevating ATP levels. This scenario
would subsequently lead to P2Y purinergic receptor activation above an
unknown threshold to produce conditions favorable to pathological
angiogenesis.
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sassociated with tumour growth as a source of triphospho-
nucleotide donor.
We are aware that 435S carcinoma cells exhibit both breast
cancer and melanoma characteristics (Sellappan et al, 2004). This
fact strengthens our observation that NDPK-P2Y angiogenic
signalling may be utilised in a broad range of tumours. P2Y
receptor signalling has also been observed to modulate prolifera-
tion of various carcinomas in a positive, and negative fashion
(White and Burnstock, 2006). One possible explanation is that
these differing effects on proliferation reflect which cancers
pathologically secrete NDPK.
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